Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions
Texas Attorney General Ken Paxton on Thursday sued Sanofi for allegedly "bribing" providers to prescribe its medications over alternatives.
Drugmaker Sanofi to expand India GCC, increase workforce to over 4,500 employees
French drugmaker Sanofi said on Monday it will expand its global capability centre (GCC) in the southern Indian city of Hyderabad, and increase its workforce to more than 4,500 employees.
SNY Stock Falls After Board Suddenly Makes Leadership Change
Sanofi stock slides 4.5% after it decides not to renew CEO Paul Hudson's mandate and names Belen Garijo as successor amid investor skepticism.
Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued
Sanofi reported FY net sales up >9% to €43.6bn and net income up >12% to €9.5mn. Despite strong results, Sanofi announced today it has replaced CEO Paul Hudson with former employee Belén Garijo, signaling urgency for improved execution and R&D innovation. Sanofi remains heavily reliant on Dupixent, which generated ~€15.7bn, or 36% of total 2024 revenues.
Who is Sanofi's new CEO Belén Garijo?
French drugmaker Sanofi on Thursday appointed Belén Garijo as its new chief executive after choosing not to renew the mandate of Paul Hudson.
Sanofi Names Merck KGaA's Garijo to Replace Hudson as CEO
Garijo steps in after the drugmaker's board of directors decided not to renew Hudson's mandate.
Sanofi appoints Belén Garijo as new CEO after deciding not to renew current CEO Hudson's mandate
French drugmaker Sanofi said on Thursday it had appointed Belén Garijo as its new chief executive after deciding not to renew the mandate of current CEO Paul Hudson.
SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status
Sanofi wins FDA Breakthrough Therapy and Japan Orphan designations for Wayrilz in wAIHA, backed by LUMINA data and a late-stage study.
Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study
SNY's phase III LEAP2MONO study meets all primary endpoints, with venglustat improving neurological symptoms in type 3 Gaucher disease patients.
UK industry body says Sanofi in breach over RSV therapy claims against Pfizer
Sanofi has breached the UK pharma code of practice with unsubstantiated claims that its Beyfortus was more effective than Pfizer's RSV vaccine, the industry's self-regulatory body said on Monday, responding to a complaint.
Sanofi's genetic disorder drug shows mixed results in late-stage trials
French drugmaker Sanofi said on Monday that its experimental genetic disorder treatment showed promise in a late-stage study of patients with a type of Gaucher disease, but failed to meet the main goal in a separate trial.
Sanofi Beats on Q4 Earnings, Expects Profitable Growth in 2026
Sanofi SNY reported fourth-quarter 2025 adjusted earnings of 89 cents per American depositary share, which beat the Zacks Consensus Estimate of 84 cents. Earnings of €1.53 per share rose 16.8% on a reported basis and 26.7% on a constant currency rate (“CER”) basis, driven by cost control.
